BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29103138)

  • 21. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M; Watanabe K; Fukuda T; Miura O
    Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects and influencing factors in sixty-eight cases of peripheral T-cell lymphoma unspecified.
    Kangsheng G; Di W; Jingjing W
    Tumori; 2014; 100(1):21-5. PubMed ID: 24675486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma.
    Hong H; Fang X; Huang H; Wang Z; Lin T; Yao H
    Br J Haematol; 2020 Jun; 189(5):908-912. PubMed ID: 32103494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
    Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
    Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
    Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
    Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
    Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Tomita N; Motomura S; Hyo R; Takasaki H; Takemura S; Taguchi J; Fujisawa S; Ogawa K; Ishigatsubo Y; Takeuchi K
    Cancer; 2007 Mar; 109(6):1146-51. PubMed ID: 17311304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
    Liu XJ; Guo Y; Fan Y; Gu KS; Cao JN; Wu XH; Zhang J; Li XQ; Wang CF; Hong XN
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):387-95. PubMed ID: 21789688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
    Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
    Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
    Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
    Rodriguez J; Munsell M; Yazji S; Hagemeister FB; Younes A; Andersson B; Giralt S; Gajewski J; de Lima M; Couriel D; Romaguera J; Cabanillas FF; Champlin RE; Khouri IF
    J Clin Oncol; 2001 Sep; 19(17):3766-70. PubMed ID: 11533100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
    Tomita N; Hattori Y; Fujisawa S; Hashimoto C; Taguchi J; Takasaki H; Sakai R; Tateishi U; Ishigatsubo Y
    Ann Hematol; 2015 Mar; 94(3):431-6. PubMed ID: 25338967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary breast peripheral T-cell lymphoma not otherwise specified: report of a case.
    Muroya D; Toh U; Iwakuma N; Nakagawa S; Mishima M; Takahashi R; Takenaka M; Shirouzu K; Agaki Y
    Surg Today; 2015 Jan; 45(1):115-20. PubMed ID: 24395027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Experience in treating peripheral T-cell lymphomas by a new program].
    Butenko AK
    Lik Sprava; 1996; (7-9):160-2. PubMed ID: 9072239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.
    Pellegrini C; Argnani L; Broccoli A; Stefoni V; Derenzini E; Gandolfi L; Casadei B; Maglie R; Pileri S; Zinzani PL
    Oncologist; 2014 Jul; 19(7):746-50. PubMed ID: 24869930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.